EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
June 26, 2024 19:03 ET
|
Genmab A/S
Company Announcement Approval based on results from Phase 1/2 EPCORE® NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R FL...
Transactions in Connection with Share Buy-back Program
June 24, 2024 09:55 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 24, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
June 18, 2024 14:45 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 18, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,986 shares as a consequence of the exercise of employee warrants. The...
Transactions in Connection with Share Buy-back Program
June 17, 2024 09:33 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 17, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
June 12, 2024 15:45 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
June 11, 2024 14:50 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 11, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Transactions in Connection with Share Buy-back Program
June 10, 2024 10:18 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 10, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 12:51 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; June 05, 2024Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Operating Officer Anthony Mancini will participate...
Transactions in Connection with Share Buy-back Program
June 03, 2024 09:09 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 3, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
June 03, 2024 09:00 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; June 3, 2024 Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in patients with recurrent or metastatic HNSCC,...